To evaluate the effect size of UGT1A1 variations on infection outcomes, we first calculated the percentage of either HBV serological phasing, LC/HCC, or HBsAg clearance in all 23 observed UGT1A1 variation combinations (including the wild type) and directly sorted them in descending order according to their occurrences, with no classification. This evidence concerns the gene UGT1A1 and laryngotracheoesophageal cleft.